Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,700 full-time employees. The company went IPO on 2015-09-18. The firm's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. The company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
The most recent EPS for Penumbra Inc is $0.82, not beating expectations of $1.08.
How did Penumbra Inc PEN's revenue perform in the last quarter?
Penumbra Inc revenue for the last quarter is $0.82
What is the revenue estimate for Penumbra Inc?
According to 17 of Wall street analyst, the revenue estimate of Penumbra Inc range from $430.34M to $384.65M
What's the earning quality score for Penumbra Inc?
Penumbra Inc has a earning quality score of B+/51.26871. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Penumbra Inc report earnings?
Penumbra Inc next earnings report is expected in 2026-08-04
What are Penumbra Inc's expected earnings?
Penumbra Inc expected earnings is $374.81M, according to wall-street analysts.
Did Penumbra Inc beat earnings expectations?
Penumbra Inc recent earnings of $374.75M does not beat expectations.